EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced Non-Squamous Non-Small-Cell lung cancer

Hui Yu, Jingyu Chen, Yixin Zhou, Jin Sheng, Xuanye Zhang, Lina He, Likun Chen, Qian Chu, Li Zhang, Shaodong Hong

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.111138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Hui Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, China; Guangdong Provincial Clinical Research Center for Cancer, Guangz…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Planning Project of Guangdong Province, National Natural Science Foundation of China, Sun Yat-sen University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Baseline corticosteroids exposure is associated with inferior clinical outcomes in patients with non-small-cell lung cancer (NSCLC) treated with programmed cell death-1 (PD-1) axis blockade. Dexamethasone is a potent corticosteroid used in the prevention of chemotherapy-associated adverse events (CAAEs). OBJECTIVE: Since dexamethasone has immunosuppressive properties, this study attempted to elucidate its effects on the efficacy of immunotherapy plus chemotherapy in patients with non-squamous NSCLC. METHODS: The study retrospectively analyzed the medical records of 254 advanced non-squamous NSCLC patients who received front-line treatment with a PD-1 pathway inhibitor and platinum-based chemotherapy at three academic institutions. The average dosage of prophylactic dexamethasone per chemotherapy cycle was calculated. Patients were divided into three groups based on the dose of dexamethasone: High-d (≥24 mg), Moderate-d (12-24 mg), and Low-d (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsDrug-Related Side Effects and Adverse ReactionsHumansImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorRetrospective StudiesDexamethasone

Stichwörter der Autor:innen

ChemotherapyDexamethasoneEfficacyImmune checkpoint inhibitorsNon–small-cell lung cancer

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorDexamethasone

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, China; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong 510060, China; Department of Medical Oncology, Sun Yat-…
  • Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
  • State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, China; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong 510060, China; Department of VIP Region, Sun Yat-sen Un…
  • Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Zhejiang 310018, Hangzhou, China.
  • Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Electronic address: qianchu@tjh.tjmu.edu.cn.

Förderung

  • Science and Technology Planning Project of Guangdong Province
  • National Natural Science Foundation of China
  • Sun Yat-sen University
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Yu, H., Chen, J., Zhou, Y., Sheng, J., Zhang, X., He, L., Chen, L., Chu, Q., Zhang, L., & Hong, S. (2023). Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced Non-Squamous Non-Small-Cell lung cancer. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.111138

Vancouver

Yu H, Chen J, Zhou Y, Sheng J, Zhang X, He L, et al. Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced Non-Squamous Non-Small-Cell lung cancer. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.111138

BibTeX
@article{Yu2023,
  author = {Yu, Hui and Chen, Jingyu and Zhou, Yixin and Sheng, Jin and Zhang, Xuanye and He, Lina and Chen, Likun and Chu, Qian and Zhang, Li and Hong, Shaodong},
  title = {Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced Non-Squamous Non-Small-Cell lung cancer},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.111138}
}
Kostenlos starten →